Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mOPV2 Immunogenicity at Varying Intervals and with IPV
NCT02643368Phase 4Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Monovalent Oral Polio Vaccine Sabin strain in poliomyelitis (4 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Assessment of type 2 immunogenicity. Started Dec 2015; status: completed.
02
Drugs
Monovalent Oral Polio Vaccine Sabin strain
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT02643368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643368.